UNSPSC 51292016: Sertraline

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C17H17Cl2N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QUC7NX6WMB, chemically known as (1s,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphthalenamine but generally known as sertraline, which bears US NIH Compound Identifier 5203. European Medicines Agency schedules Sertraline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10499MIG.

UNSPSC 51292016 Sertraline is a Commodity code that nominally refers to a single pharmaceutical product, but recent state and local procurement activity under this code classification does not reflect purchases of sertraline itself. Instead, the code appears in solicitations for broader pharmaceutical procurement frameworks, naloxone and drug deactivation systems, and multi-source generic pharmaceuticals and over-the-counter products distributed through state and local health systems and cooperative purchasing alliances. The actual work being solicited involves establishing supply contracts for pharmaceutical products and related health commodities, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, insurance requirements (including commercial general liability up to $5 million per occurrence), and integration with authorized wholesaler networks.

Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances spanning multiple states and local jurisdictions. Recent solicitations show activity in Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries and a two-year initial term; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs prior to formal competitive solicitation; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract effectiveness July 1, 2026 and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on administrative compliance and capability factors.